Novel drug combination treatment for tuberculosis
Tuberculosis (TB) is still the world's most deadly infectious disease, and multidrug-resistant TB poses a serious threat to global health. Treatment options are limited and often associated with many adverse effects from the drugs. The overall objective of the EU-funded RespiriTB project is to find new drug candidates for efficient combination treatment against TB and multidrug-resistant TB. The drug combination will target the energy metabolism of Mycobacterium tuberculosis (Mtb), using recently discovered inhibitors of the Mtb respiratory pathway. It will also target host factors that are essential for the intracellular survival of Mtb. The project presents a comprehensive plan to find novel strategies to combat TB, shorten treatment time and reduce incidences of drug resistance.
Fields of science
Call for proposal
See other projects for this call
Funding SchemeIMI2-RIA - Research and Innovation action
1391 JM Abcoude